65,437 trials
Amyotrophic Lateral Sclerosis
Primary: Change in ALS Functional Rating Scale - Revised (ALSFRS-R) — -0.905; -0.983; -0.743 scores on a scale
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…
Major Depressive Disorder
Primary: Mood Symptoms Ratings — 33.0; 33.1 CDRS-R score
Diabetes Mellitus
Primary: Change in Confidence in Ability to Perform Teamwork — 1.40; -0.12 units of a scale — p=0.04
Raynaud
Primary: Number of Raynaud's Phenomenon Attacks Per Day — 2.4; 1.1; 2.0; 2.3 Raynaud's attacks per day
Osteoarthritis
Primary: Stair Time up — 7; 8 seconds
Hyperphosphatemia · End-Stage Renal Disease
Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Disease Progression or Death — 29.7; 34.7 percentage of participants — p=0.254
Stroke · Hemiplegic Gait
Primary: 6 Minute Walk Test (Metres) — 54.3 metres
Head and Neck Neoplasms · Cancer of the Head and Neck
Primary: To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and…
Ovarian Cancer
Primary: Percentage of Participants With Disease Progression or Death — 87.8; 80.0 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel — 0; 2; 0; 1 Participants
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change of Morisky Medication Adherence Scale -8 (MMAS-8) Score at the End of the Educational Period After 6 Months From Baseline — 0.6 units on a scale — p=<0.0001
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline ADHD Rating Scale-IV Scores at 8 Weeks — 14.9 units on a scale